Last reviewed · How we verify

Novosis(bongros/BMP-2) — Competitive Intelligence Brief

Novosis(bongros/BMP-2) (Novosis(bongros/BMP-2)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant protein growth factor. Area: Orthopedics / Bone regeneration.

phase 3 Recombinant protein growth factor BMP-2 receptor (ALK2/ALK3) Orthopedics / Bone regeneration Small molecule Live · refreshed every 30 min

Target snapshot

Novosis(bongros/BMP-2) (Novosis(bongros/BMP-2)) — Daewoong Pharmaceutical Co. LTD.. Novosis is a recombinant human bone morphogenetic protein-2 (BMP-2) that promotes bone formation by stimulating osteoblast differentiation and new bone growth.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Novosis(bongros/BMP-2) TARGET Novosis(bongros/BMP-2) Daewoong Pharmaceutical Co. LTD. phase 3 Recombinant protein growth factor BMP-2 receptor (ALK2/ALK3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant protein growth factor class)

  1. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Novosis(bongros/BMP-2) — Competitive Intelligence Brief. https://druglandscape.com/ci/novosis-bongros-bmp-2. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: